Skip to content

Maryland · Nonprofit

ASSOCIATION FOR MOLECULAR PATHOLOGY INC

ASSOCIATION FOR MOLECULAR PATHOLOGY INC (Maryland) receives grants from 2 organizations whose IRS filings report $150,000 to it, the largest being Illumina Corporate Foundation ($75,000). 1 of them have funded it in more than one year.

Revenue FY2024
$6.3M
Funders on record
2
Grants received
$150k
Net assets
$12M
1/2 repeat funderspeak grant-dependency 2%
01What it does

What Association for Molecular Pathology Inc does

Mission

Advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy to enable highest quality health care.

As stated on its FY2024 Form 990.

Programs

  1. Scientific symposia and meetings - see schedule o for complete description

    $2,845,984 spentof which $37,425 as grants$4,154,655 earned by the program
    51% of program spending
  2. Communication & outreach: membership services - website, newsletters, etc.promote general effectiveness and provide a forum for discussion and a means of exchanging information.

    $320,975 spent$467,403 earned by the program
    6% of program spending
  3. Innovation and improved patient care (iipc) - see schedule o for complete descriptioniipc works to foster innovation to improve patient care and patient outcomes through programs that include issuing manuscripts, clinical practice guidelines, reports, and oversight of jmd's strategic direction.the journal of molecular diagnosticsthis is the official journal of amp. Monthly publication began in january 2020. These issues have original, high-quality manuscripts on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine.every published manuscript is scientifically peer reviewed.jmd is jointly owned with the american society for investigative pathology (asip) 94-6079945. Starting in 2011, elsevier began publishing jmd.

    $558,685 spent$72,723 earned by the program
    10% of program spending
  4. Advocacythe amp advocacy program endeavors to inform and influence public policy affecting molecular pathology. Amp represents its membership to the federal agencies and members of congress regarding professional and reimbursement issues - reaching out to fellow professional associations, industry and other association partners to accomplish common goals.

    $1,862,651 spent
    33% of program spending

The 4 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $5,588,295.

02The organization over time

The organization over time

Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.

100 = 20172017 Revenue 100 ($4.9M) Expenses 100 ($4.1M) Net assets 100 ($9.8M)2018 Revenue 123 ($6.0M) Expenses 124 ($5.1M) Net assets 105 ($10M)2019 Revenue 129 ($6.3M) Expenses 137 ($5.6M) Net assets 121 ($12M)2020 Revenue 81 ($3.9M) Expenses 108 ($4.4M) Net assets 125 ($12M)2021 Revenue 88 ($4.3M) Expenses 113 ($4.6M) Net assets 129 ($13M)2022 Revenue 182 ($8.9M) Expenses 142 ($5.8M) Net assets 125 ($12M)2023 Revenue 130 ($6.4M) Expenses 158 ($6.5M) Net assets 133 ($13M)2024 Revenue 129 ($6.3M) Expenses 184 ($7.5M) Net assets 127 ($12M)
'17'18'19'20'21'22'23'24
Revenue (129)Expenses (184)Net assets (127)Peer revenue range

Balance sheet

Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2017 to 2018, from $11M to $13M (+23%).

$11M
$13M
$15M
$16M
$16M
$15M
$16M
$16M
'17'18'19'20'21'22'23'24
Total assetsTotal liabilities

How it's funded, over time

Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.

2017
2018
2019
2020
2021
2022
2023
2024
ContributionsProgram revenueInvestmentOther

17% of ASSOCIATION FOR MOLECULAR PATHOLOGY INC’s revenue is contributions — about as donation-reliant as the typical peer (48% for the typical peer).

This organization
Typical peer · 12,352 orgs

Surplus & reserves

Operating surplus or deficit each year, and months of liquidity in hand. 4 of the last 8 reported years ran a deficit.

$805k
’17
$935k
’18
$704k
’19
−$478k
’20
−$323k
’21
$3.1M
’22
−$95k
’23
−$1.2M
’24
2.7
months of
reserve

Leadership and staff

The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.

'17'18'19'20'21'22'23'24
Listed2222232323232534
Joined·+5+8+7+7+10+10+14
No longer listed·57771085
03Who funds it

Who funds it, year by year

2017 → 2022: the base held at 1 funder, grant income held at $10k.

From the IRS filings of ASSOCIATION FOR MOLECULAR PATHOLOGY INC’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How concentrated its funding is

ASSOCIATION FOR MOLECULAR PATHOLOGY INC leans on a few funders — its largest provides 50% of grant income and the top three 100%; half comes from just 1 funder.

the vertical line marks half of all grant income — 1 funder to its left

50%
largest funder
100%
top three
~2
effective funders

Largest funder’s share by year: 2017 100% · 2019 100% · 2020 100% · 2021 88% · 2022 100% — broadly stable.

“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

Where its funders are

ASSOCIATION FOR MOLECULAR PATHOLOGY INC draws 100% of its grant income from funders outside Maryland, across 2 states in all.

OH
DE

In-state vs out-of-state, by year

’17
’19
’20
’21
’22
Maryland out of state home

Funder states come from each funder’s own filing. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

04Its place in the field

Against its field

ASSOCIATION FOR MOLECULAR PATHOLOGY INC's revenue grew 29% between 2017 and 2024.

Operating margin−19% · bottom quartile
Months of reserve2.7mo · below the median
Revenue growth (annualized)4% · below the median

this organization peer median middle 50% of peers· 11,752 education nonprofits $1M–$10M, FY2024

Organizations like ASSOCIATION FOR MOLECULAR PATHOLOGY INC

Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.

In Maryland

Nationally

05Profile & governance

Read directly from this organization’s own Form 990, as neutral context.

Where the money goes

75% of spending goes to programs.

Program 75%Management 25%Fundraising 0%

Governance

19
board members
100%
independent
✓Conflict-of-interest policy✓Whistleblower policy✓Document retention✓Board reviewed the 990✓Audited financials

Public support

93%

Share of support from the public (Schedule A) — the basis for its public-charity status.

Screen this organization

A dated, signed PDF of the compliance screen for ASSOCIATION FOR MOLECULAR PATHOLOGY INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.

A paid feature, included from the $75 plan up. Sign in to download.

Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf

Questions and answers

Who funds ASSOCIATION FOR MOLECULAR PATHOLOGY INC?
ASSOCIATION FOR MOLECULAR PATHOLOGY INC (Maryland) receives grants from 2 organizations whose IRS filings report $150,000 to it, the largest being Illumina Corporate Foundation ($75,000). 1 of them have funded it in more than one year.
How many funders does ASSOCIATION FOR MOLECULAR PATHOLOGY INC have?
IRS filings report 2 organizations giving $150,000 in grants to ASSOCIATION FOR MOLECULAR PATHOLOGY INC, 1 of which have funded it in more than one year.
Who is the largest funder of ASSOCIATION FOR MOLECULAR PATHOLOGY INC?
Illumina Corporate Foundation is the largest funder on record, with $75,000 in grants. The full list of funders is on this page.
How can an organization like ASSOCIATION FOR MOLECULAR PATHOLOGY INC find more funders?
Start with the funders already giving here, then look at the foundations that back similar organizations in Maryland. The funding by cause and by state pages list the largest funders for a given area and how to approach them.

Play a game about who funds Association for Molecular Pathology →

These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 2 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing